Eli Lilly and Company (NYSE:LLY) Stock Rating Reaffirmed by Cantor Fitzgerald

Eli Lilly and Company (NYSE:LLY)‘s stock had its “overweight” rating restated by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $885.00 price objective on the stock. Cantor Fitzgerald’s price target would indicate a potential downside of 2.20% from the stock’s current price.

A number of other equities research analysts have also issued reports on LLY. Jefferies Financial Group lifted their target price on Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Truist Financial increased their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research report on Wednesday, May 1st. Bank of America increased their price objective on Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Argus increased their price objective on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research report on Tuesday, May 14th. Finally, JPMorgan Chase & Co. raised their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $812.72.

Eli Lilly and Company Price Performance

LLY stock opened at $904.95 on Monday. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a one year low of $434.34 and a one year high of $909.42. The firm has a market capitalization of $860.07 billion, a PE ratio of 133.28, a P/E/G ratio of 1.93 and a beta of 0.36. The firm has a 50-day moving average of $804.54 and a two-hundred day moving average of $734.18.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter in the prior year, the business earned $1.62 earnings per share. The company’s revenue was up 26.0% on a year-over-year basis. On average, analysts forecast that Eli Lilly and Company will post 13.73 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 9,671 shares of the company’s stock in a transaction dated Thursday, June 20th. The shares were sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the completion of the transaction, the insider now owns 97,574,139 shares of the company’s stock, valued at $88,077,248,051.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other Eli Lilly and Company news, EVP Johna Norton sold 7,056 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.38, for a total value of $5,781,545.28. Following the sale, the executive vice president now directly owns 25,428 shares in the company, valued at $20,835,194.64. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 9,671 shares of the stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $902.67, for a total transaction of $8,729,721.57. Following the completion of the sale, the insider now owns 97,574,139 shares in the company, valued at $88,077,248,051.13. The disclosure for this sale can be found here. Insiders sold a total of 789,704 shares of company stock valued at $672,385,964 in the last quarter. Insiders own 0.13% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LLY. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $26,000. Tidemark LLC acquired a new position in Eli Lilly and Company during the fourth quarter worth $29,000. Core Wealth Advisors Inc. grew its stake in shares of Eli Lilly and Company by 188.2% in the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after acquiring an additional 32 shares in the last quarter. Frank Rimerman Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 4th quarter worth $37,000. Finally, St. Johns Investment Management Company LLC grew its stake in shares of Eli Lilly and Company by 123.3% in the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after acquiring an additional 37 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.